Karie Runcie
About
Karie Runcie is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Karie Runcie has authored 27 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Karie Runcie's work include Prostate Cancer Treatment and Research (10 papers), Renal cell carcinoma treatment (9 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Karie Runcie is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Renal cell carcinoma treatment (9 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Karie Runcie collaborates with scholars based in United States, Australia and China. Karie Runcie's co-authors include Daniel R. Budman, Nagashree Seetharamu, Veena S. John, Matthew C. Dallos, Eric A. Singer, Shawn Dason, Raquibul Hannan, Yuanquan Yang, Mark N. Stein and Vivek Narayan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.
In The Last Decade
Karie Runcie
22 papers receiving 225 citations
Peers
Karie Runcie
Veena S. John United States
Sundee Dees United States
Stephanie O. Dudzinski United States
Silvia Esposito Italy
Camilo Garcia France
Merel van Gogh Switzerland
Jinzhi Lai China
Azam Ghafoor United States
Divya Nagarajan United Kingdom
Varvara Polydoropoulou Greece
Citations per year, relative to Karie Runcie Karie Runcie (= 1×)
peers
Veena S. John
Countries citing papers authored by Karie Runcie
Since
Specialization
Citations
This map shows the geographic impact of Karie Runcie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karie Runcie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karie Runcie more than expected).
Fields of papers citing papers by Karie Runcie
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Karie Runcie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karie Runcie. The network helps show where Karie Runcie may publish in the future.
Co-authorship network of co-authors of Karie Runcie
This figure shows the co-authorship network connecting the top 25 collaborators of Karie Runcie. A scholar is included among the top collaborators of Karie Runcie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karie Runcie. Karie Runcie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Azad, Arun, Qiang Dong, Alicia K. Morgans, et al.. (2025). Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 43(5_suppl). 147–147.
2.
Kim, Isaac Yi, Vivian Wong, Karie Runcie, & Eric A. Singer. (2025). Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions. PubMed. 7(2). 81–94.
3.
Wei, Alexander Z., Basil Bakir, Andrew T. Lenis, et al.. (2025). A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT).. Journal of Clinical Oncology. 43(5_suppl).
4.
Runcie, Karie, Alexander Z. Wei, Mark N. Stein, et al.. (2025). QUALITY OF LIFE, DECISIONAL REGRET, AND FEAR OF RECURRENCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER MANAGED WITH SURVEILLANCE AFTER CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY. Urologic Oncology Seminars and Original Investigations. 43(3). 16–16.
5.
Christin, John R., Alexander Z. Wei, Karie Runcie, et al.. (2025). Management of Patients with Muscle-Invasive Bladder Cancer Achieving A Clinical Complete Response after Neoadjuvant Therapy: Evidence and Consideration for Active Surveillance. Current Urology Reports. 26(1). 36–36.
6.
Runcie, Karie, et al.. (2024). Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. The Oncologist. 30(1).
7.
Patel, Manish R., Jessica E. Hawley, S. Srinivas, et al.. (2024). 1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 35. S962–S963.
8.
Stein, Mark N., et al.. (2024). Adjuvant therapy in renal cell carcinoma (RCC): progress, at last. Translational Cancer Research. 13(11). 6448–6462.
9.
Runcie, Karie, et al.. (2024). Positive psychology interventions in patients with prostate cancer: A systematic review.. Journal of Clinical Oncology. 42(16_suppl). e17005–e17005.
10.
Stein, Mark N., Laura Graham, Armelle Vinceneux, et al.. (2024). 1659TiP A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer. Annals of Oncology. 35. S1000–S1000.
11.
Rathkopf, Dana E., Manish R. Patel, Atish D. Choudhury, et al.. (2024). First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 134–134.
12.
Jegede, Opeyemi A., Mehmet Asım Bilen, David A. Braun, et al.. (2024). Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).. Journal of Clinical Oncology. 42(4_suppl). TPS492–TPS492.
13.
Azad, Arun, Qiang Dong, Alicia K. Morgans, et al.. (2024). Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.. Journal of Clinical Oncology. 42(4_suppl). TPS236–TPS236.
14.
McKay, Rana R., Lin Liu, Minya Pu, et al.. (2024). A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).. Journal of Clinical Oncology. 42(16_suppl). TPS5128–TPS5128.
15.
Runcie, Karie, et al.. (2023). Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy. SHILAP Revista de lepidopterología. 10(3). 37–60.
16.
Yang, Yuanquan, et al.. (2023). Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. Current Opinion in Oncology. 35(3). 206–217.
17.
Hawley, Jessica E., Matthew C. Dallos, Emerson A. Lim, et al.. (2023). The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology. 41(16_suppl). e17089–e17089.
18.
Dallos, Matthew C., Samuel Pan, Matthew G. Chaimowitz, et al.. (2022). A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).. Journal of Clinical Oncology. 40(16_suppl). 5082–5082.
19.
Runcie, Karie, Daniel R. Budman, Veena S. John, & Nagashree Seetharamu. (2018). Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Molecular Medicine. 24(1). 50–50.
20.
Runcie, Karie & Tomer M. Mark. (2015). Novel Induction Regimens in Multiple Myeloma. Current Hematologic Malignancy Reports. 10(4). 388–394.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Veena S. John Breakdown of academic impact, for papers by Sundee Dees Breakdown of academic impact, for papers by Stephanie O. Dudzinski Breakdown of academic impact, for papers by Silvia Esposito Breakdown of academic impact, for papers by Camilo Garcia Breakdown of academic impact, for papers by Merel van Gogh Breakdown of academic impact, for papers by Jinzhi Lai Breakdown of academic impact, for papers by Azam Ghafoor Breakdown of academic impact, for papers by Divya Nagarajan Breakdown of academic impact, for papers by Varvara Polydoropoulou